Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Daniel Prieto-Alhambra of NDORMS will lead a work package on the generation of evidence from European wide observational data as part of a new Innovative Medicines Initiative project, the European Health Data & Evidence Network (EHDEN).

None

The five-year IMI2 EHDEN programme will harmonise clinical data and develop a 21st century ecosystem for real world health research in Europe

"We are extremely excited to contribute to this project. EHDEN will be a game-changer for European international collaboration in observational research", says Professor Prieto-Alhambra.

Today, in Europe, we are challenged to generate insights and evidence from real world clinical data at scale, to support patients, clinicians, payers, regulators, governments, and the pharmaceutical industry in understanding wellbeing, disease, treatments, outcomes and new therapeutics and devices. Unfortunately, such data is difficult to use at scale, in a myriad of languages, systems and structures, with challenging policy restrictions and technology considerations.

Consequently, using real world data for research, reflective of what happens for patients in their own experience of healthcare, is very challenging. “Every day, patients throughout Europe are being denied optimal care because we are not able to create sufficient insights that lead to improved systems, services, and new treatment options,” said Nicola Bedlington, Secretary General, European Patients Forum, an EHDEN partner.

In response to this, the EHDEN public private project was set up under the framework of IMI2, with twenty-two partners, including academia, SMEs, patient associations, regulatory authorities and pharmaceutical companies, led by Erasmus Medical Centre, The Netherlands, and Janssen Pharmaceutica N.V., Belgium. The mission of EHDEN is to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model. EHDEN will build on prior projects, such as EMIF and EHR4CR, in scaling their original intents and technologies.

Dr Peter Rijnbeek, Erasmus MC, Coordinator of EHDEN stated, “We have a critical need to improve how we conduct health research at scale, across borders throughout Europe. We need to develop the technical infrastructure, partnerships and collaborations to support this.” EHDEN will establish a federated network of data sources, such as hospitals and primary care networks across Europe.

Central to EHDEN will be the standardisation of health data to the OMOP common data model and the utilisation of analytical tools such as those developed by the international Observational Health Data Sciences and Informatics (OHDSI) open science collaboration (www.ohdsi.org), and others. A network of SMEs will be trained and certified to ensure high validity transformation of data to the common data model.

EHDEN’s aspirations are significant, aiming to harmonise 100 million, anonymised health records across multiple data sources, who can obtain funding from the EHDEN Harmonisation Fund to obtain support from certified/qualified SMEs through serial open calls. The project will support other IMI2 projects within a wider Big Data for Better Outcomes (BD4BO) programme, other IMI and non-IMI projects, and will collaborate strongly with other key stakeholders in Europe, such as the European Medicines Agency.

“We believe EHDEN is a flagship project, and it will be significantly influential,” said Nigel Hughes, Project Leader for EHDEN at Janssen, “building on the heritage and developments of prior and current projects in and out of IMI, and it will establish 21st century tools for 21st research.” Peter Rijnbeek added, “As such it will impact on European health records research for years and decades to come, and will enable better health decisions, outcomes and care.”

For more information please contact the project via enquiries@EHDEN.eu.

Similar stories

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

Vascular loss shown to be the primary hallmark of aging

Kennedy Main Tissue remodelling and regeneration

New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.

Understanding the first wave of COVID-19 and implications for tackling the ongoing pandemic: evidence from 5.5 million people from Catalonia, Spain

Botnar Main Research Statistics and epidemiology

Health outcomes during the first wave of COVID-19 in Catalonia, Spain, have been described in detail in a study published by Nature Communications.